GUANGZHOU, CHINA, March 29, 2018 – Bio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company will present two posters at the 2018 American Association for Cancer Research ("AACR") Annual Meeting taking place April 14 - 18, 2018 in Chicago, Illinois.

?

The first poster, entitled “BAT1706 demonstrates high similarity to Bevacizumab in comparative analysis with originator in Phase I clinical trials in New Zealand and China,” will highlight Phase I clinical data showing the biosimilarity between BAT1706, Bio-Thera’s bevacizumab biosimilar, and bevacizumab. An abstract of the presentation will be available on AACR website on the day of the presentation.

?

Presentation details are as follows:

Session Category: ? ? ? ? ? ?? Clinical Research

Session Title: ? ? ? ? ? ? ? ? ? ? ??Phase I Clinical Trials 2

Session Date and Time:??Monday, April 16, 2018, 8:00 AM - 12:00 PM

Location:? ? ? ? ? ? ? ? ? ? ? ??? ? ? ?McCormick Place South, Exhibit Hall A, Poster Section 42

Poster Board Number:?? ? ?? 16

?

The second poster, entitled “BAT4306F, an anti-CD20 antibody devoid of fucose modification, demonstrates enhanced ADCC effect and potent in vivo efficacy,” will highlight preclinical data evaluating our novel ADCC-enhanced anti-CD20 mAb, which will begin a Phase I clinical trial later this year. An abstract of the presentation is currently available on AACR website.

?

Presentation details are as follows:

Session Category: ? ? ? ? ????Immunology

Session Title:???????????????????? Therapeutic Antibodies, Including Engineered Antibodies 3

Session Date and Time: ?? Tuesday April 17, 2018 8:00 AM - 12:00 PM

Location: ? ? ? ? ? ? ? ? ? ? ? ??? ? McCormick Place South, Exhibit Hall A, Poster Section 34

Poster Board Number:???????? 13

Abstract Number:??????? ? ? ? ? ? ? 3823

?

Copies of both posters will be made available on the Company's website after they are presented.

?

About BAT1706

BAT1706 is an anticancer monoclonal antibody (mAb) biosimilar being developed to treat a variety of cancers, including non-small cell lung cancer, that are currently approved indications of the reference product, bevacizumab. BAT1706 has successfully completed preclinical development and two Phase I clinical trials. BAT1706 is currently being evaluated in a global Phase III clinical trial that will demonstrate the efficacy and safety of BAT1706 is similar to the reference product, bevacizumab.

?

About BAT4306F

BAT4306F is an investigational, monoclonal antibody targeting the CD20 receptor. The CD20 receptor is a validated drug target with monoclonal antibodies approved to treat lymphoma, rheumatoid arthritis, multiple sclerosis and lupus. BAT4306F is an ADCC-enhanced antibody that has demonstrated potent in vitro and in vivo efficacy in models of lymphoma.?

?

About Bio-Thera Solutions

Bio-Thera Solutions is a clinical-stage biopharmaceutical company focused on innovative therapeutics and biosimilars. Bio-Thera is developing a pipeline of ADCC-enhanced monoclonal antibodies, antibody-drug conjugates and best-in-class antibodies for the treatment of a broad range of cancers and other diseases. Bio-Thera’s biosimilar pipeline is focused on autoimmune and oncology therapeutics. The company is headquartered in Guangzhou, China and has more than 350 employees. Learn more at http://www.bio-thera.com/EN/. Follow Bio-Thera Solutions on Twitter at @bio_thera_sol